| abstract |
The invention described herein is directed to the compounds of Formula I (see Formula) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreas, chronic human lymphocytic leukemia, melanoma cancers. and others. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt thereof. The invention described herein is also directed to methods for treating prostate, breast, ovarian, liver, kidney, colon, pancreas, chronic human lymphocytic leukemia, melanoma and others. The invention described herein is further directed to methods for treating prostate, breast, colon, pancreas, chronic lymphocytic leukemia, melanoma and others, comprising the administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. |